Statement Of Cash Flows [Abstract]

Marinomed Biotech AG - Filing #1079021

Concept 2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income
0 EUR
5,230,000 EUR
Adjustments to reconcile profit (loss) other than changes in working capital
1,630,000 EUR
2,478,000 EUR
Adjustments for decrease (increase) in trade and other receivables
7,848,000 EUR
2,043 EUR
Adjustments for increase (decrease) in trade and other payables
8,476,000 EUR
1,337 EUR
Adjustments for decrease (increase) in other assets
83,000 EUR
4,000 EUR
Adjustments for gain (loss) on disposals, property, plant and equipment
- EUR
10,000 EUR
Finance costs paid, classified as operating activities
3,576,000 EUR
2,120,000 EUR
Finance income received, classified as operating activities
0 EUR
1,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from exercise of options
3,041,000 EUR
3,060,000 EUR
Repayments of non-current borrowings
3,000,000 EUR
2,100,000 EUR
Proceeds from issue of bonds, notes and debentures
6,000,000 EUR
- EUR
Payments for share issue costs
8,000 EUR
117,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.